Hai A, Kizilbash N. Increase in activity of Na
+, K
+-ATPase by Porphyrin compounds as treatment for Dysnatremias caused by Diabetes Mellitus.
Pak J Med Sci 2016;
32:1131-1134. [PMID:
27882008 PMCID:
PMC5103120 DOI:
10.12669/pjms.325.11530]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE
The aim of this study was to test the action of Porphyrin compounds, Tetraphenylporphine sulfonate (TPPS), 5,10,15,20-Tetrakis (4-sulfonatophenyl) porphyrinato Iron(III) Chloride (FeTPPS) and 5,10,15,20-Tetrakis (4-sulfonatophenyl) porphyrinato Iron(III) nitrosyl Chloride (FeNOTPPS), on Na+, K+ -ATPase of cell membrane of erythrocytes.
METHODS
Enzymatic assays, measuring the amount of inorganic phosphate produced, were used to estimate the activity of Na+, K+-ATPase.
RESULTS
The results show that Porphyrin compounds exert an insulin-like effect on Na+, K+-ATPase. They act by increasing the activity of the membrane-bound enzyme.
CONCLUSION
All the three Porphyrin compounds increased the activity of erythrocyte Na+, K+-ATPase. The exact mechanism of action of these compounds is not clear.
Collapse